AXGN
Axogen, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 16 ▼ 1 insider sell $171.5K at $32.84
- May 7 to May 8 ▼ 2 days of insider sells: $1.7M by 6 insiders, avg $43.64
- Aug 7 to Aug 11 ▼ 3 days of insider sells: $4.5M by 3 insiders, avg $47.19
- Sep 2 ▼ 1 insider sell $173.9K at $49.70
- Sep 10 Offering: Axogen Announces Pricing of $208.7 Million Public Offering…
- Sep 10 Axogen is conducting a $208.7M underwritten public offering of 4.91M…
- Oct 1 ▲ Axogen completed its acquisition of BioCircuit Technologies, adding…
- Oct 1 ▲ Axogen completed its acquisition of BioCircuit Technologies, develop…
- Oct 12 B of A Securities initiates
- Oct 28 ▲ Axogen reported Q3 2026 revenue of $75.8M (+26.2% YoY), above the $7…
- Oct 28 ▲ Axogen reported Q3 2026 revenue of $75.8M (+26.2% YoY), beating the…
- Oct 30 ▼ Short interest jumps 36.5% to 6.99M
Signal stack
Where each data set points today.
- InsidersBEARISH
9 insiders sold $6.5M.
- InstitutionsMIXED
Q3 2026: 23 added (1 new), 23 trimmed or exited.
- AnalystsBULLISH
16 of 17 rate it Buy or better. Every target is above the price.
- Short sellersBUILDING
Short interest +36.5% to 6.99M shares. 3.3 days to cover, ≈11.7% of shares.
- TrendUPTREND
28% above its 50-day average. New closing high $58.63 on Nov 11.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $110.6M |
| MORGAN STANLEY | TRIM | $75.0M |
| Artemis Investment Management LLP | ADD | $74.7M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $22.6M |
| Assenagon Asset Management S.A. | TRIM | $17.3M |
| Nuveen, LLC | TRIM | $14.8M |
| Russell Investments Group, Ltd. | DOUBLED | $14.0M |
| UBS Group AG | TRIM | $11.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +8%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 29, 2026 | Leerink Partners MAINTAIN | Outperform |
| Oct 29, 2026 | Barclays MAINTAIN | Overweight |
| Oct 29, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 29, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 29, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
TYNDALL JOSEPH A. Director Sep 2, 2026 | SELL | $173.9K |
Wendell Amy McBride Director Aug 11, 2026 | EXERCISE | $198.3K |
Wendell Amy McBride Director Aug 11, 2026 | SELL | $646.6K |
Began Marc A EVP & General Counsel Aug 10, 2026 | EXERCISE | $550.8K |
Began Marc A EVP & General Counsel Aug 10, 2026 | SELL | $3.2M |
Weiler Kathy Johnson Director Aug 7, 2026 | SELL | $641.0K |
Burke William P. Mr. Director Jun 24, 2026 | AWARD | 4,392 sh |
JOHNSON JOHN Director Jun 24, 2026 | AWARD | 4,392 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 3 press releases · 6 bullish · 1 bearish · 4 mixed · 5 neutral- BEARISH SC 13G/ANov 13, 2026
Morgan Stanley filed an amended Schedule 13G disclosing a 2.8% passive stake in Axogen as of…
Morgan Stanley's exit below the 5% threshold removes a large passive holder from the register. Monitor for further institutional selling pressure and whether other large holders follow suit. The…
- BULLISH 8-KNov 9, 2026
Axogen hosted an investor event announcing its decision to launch into the prostate nerve…
Monitor for initial revenue contribution from prostate procedures in upcoming quarterly filings. The launch represents a significant market expansion beyond Axogen's current peripheral nerve repair…
- NEUTRAL INST-CLUSTERNov 4, 2026
In Q3 2026, three asset managers added to AXGN positions (net +$17.6M) while three others trimmed…
The cluster shows a clear split: two active asset managers (Artemis, Dimensional) added meaningfully after the Q3 beat, while Assenagon's large trim offsets the buying. With no insider buying to…
- BULLISH 8-KOct 28, 2026
Axogen reported Q3 2026 revenue of $75.8M (+26.2% YoY), above the $73.2M consensus, and GAAP net…
The raised guidance, strong cash position after the BioCircuit acquisition, and new prostate market entry catalyst suggest accelerating growth. Watch the Nov 9 prostate investor webcast for clinical…
All AXGN filing & press-release reports (19)
- SC 13G/A reportNov 13, 2026
- 8-K reportNov 9, 2026
- INST-CLUSTER reportNov 4, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 28, 2026
- SC 13G reportOct 2, 2026
- 8-K reportOct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- 424B5 reportSep 10, 2026
- 8-K reportSep 10, 2026
- PRESS-RELEASE reportSep 10, 2026
- PRESS-RELEASE reportSep 10, 2026
- CLUSTER reportAug 12, 2026
- INST-CLUSTER reportAug 11, 2026
- 8-K reportJul 29, 2026
- PRESS-RELEASE reportJul 15, 2026
- INST-CLUSTER reportJul 9, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportMay 7, 2026